Since treatment of cells with Palbociclib mostly arrests bladder cancer cells in G0/G1 cell cycle stage by inhibiting progression into S-Phase, we examined if the synergistic drug combinations with Axitinib, Erdafitinib, CI1040 and the PI3K/mTOR inhibitor NVP-BEZ235 could induce an even greater G0/G1 arrest than monotherapy. This evidence concerns the gene MTOR and urinary bladder carcinoma.